Table 3 Cox model to assess factors associated with higher persistence with golimumab treatment.
From: Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
Variables | HR | Lower 95% CI | Upper 95% CI | P |
|---|---|---|---|---|
Previous biological agents | 1.094 | 0.742 | 1.613 | 0.651 |
Concomitant immunosuppressants | 1.183 | 0.806 | 1.738 | 0.391 |
Dose intensification | 1.519 | 1.025 | 2.249 | 0.037 |
Disease extent: left-side colitis | 1.556 | 0.556 | 4.351 | 0.40 |
Disease extent: extensive colitis | 1.486 | 0.536 | 4.116 | 0.446 |
Disease duration | 0.961 | 0.933 | 0.99 | 0.008 |
